|
⚲
|
| Keyboard |
| SV Health Investors LLC
✚
|
|
|---|---|
| CRD # | 160933 |
| SEC # | 801-110943 |
| CIK # | 0001587143 |
| AUM | 1,080.3 M (2026-03-31) |
| Employees | 26 (62% Investors, 0% Brokers) |
| Fees | |
| Minimum | |
| Phone | 617-367-8100 |
| Address | 28 State Street Boston, MA 02109 |
| Source | [IAPD] [EDGAR] [Website] [LinkedIn] |
| Total AUM ($B) |
|---|
| Fees and Compensation — Form ADV Part 2A (3/31/2026) [Brochure] |
|---|
FEES AND COMPENSATION
A. Detailed information regarding the fees that are charged to the Funds is provided in the
Offering Documents. SV is entitled to a management fee as compensation for its services,
subject to the accrual schedule listed in each Fund’s Offering Documents. Generally, each
Fund’s general partner is entitled to receive 20% of net profits of the Fund after committed
capital is returned to limited partners, subject to the limitations and disclosures made in
each Fund’s Offering Documents. Fees charged to co-investment and continuation
vehicles will vary based on negotiations with limited partners and are outlined in each such
vehicle’s Offering Documents.
B. Management fees are payable by the Funds to SV or an affiliate of SV quarterly in advance
and such fees are determined prior to the calculation or payment of any partner distribution.
The management fee is paid first from each Fund’s cash flow, and next from the proceeds
of a realization and then from any other cash funds available to any Fund. The management
fee is accrued on a day-to-day basis, where adjustments for the admission of new limited
partners or commitment increases are made pursuant to the schedule outlined in each
Fund’s Offering Documents. The management fees payable by co-investment and
continuation vehicles will vary based on negotiations with limited partners and are outlined
in each such vehicle’s Offering Documents.
C. A description of the other types of fees or expenses the Funds may pay is set forth in detail
in each Fund’s Offering Documents. The fees and expenses each Fund is generally
responsible for include, but are not limited to:
(a) All stamp duty, capital duty, registration fees or other similar duties and imposts
payable from time to time on or in respect of the Offering Documents or the Fund;
(b) all stamp and other duties, all taxes or governmental charges (including non-
recoverable value added tax), all brokerage fees, reasonable commissions, bank
charges, transfer fees, registration fees, reasonable lawyers’ and accountants’ costs
and expenses, reasonable agents’, consultants’, experts’ and other professional fees
and expenses, including costs associated with any research or investigation, and
any other reasonable duties, charges or fees incurred in connection with the
partnership assets (or assets that are intended to become and do become part of the
partnership assets) and any transactions related thereto;
(c) all third-party expenses incurred in the collection of cash flow and capital
contributions or the disbursement of partner distributions;
(d) all expenses incurred in relation to the registration of any investment interests
forming part of the partnership assets or the custody of the documents of title
thereto (including bank charges, insurance of documents of title against loss in
shipment, transit or otherwise, and charges made by agents of the general partners
for retaining documents in safe custody);
(e) all taxes payable by or on behalf of the Fund in respect of the holding of, or dealing
with, investment interests or other investments of the Fund;
(f) the reasonable remuneration and expenses of the auditors and other reasonable costs
incurred in connection with the preparation of the financial statements;
(g) the Fund’s proportionate share of any reasonable costs reimbursable to the advisory
committee (the “Advisory Committee”);
(h) the costs of maintaining records and books of account in relation to the business of
the Fund;
(i) any interest on borrowings and any reasonable expenses incurred in negotiating,
entering into, effecting, maintaining, varying and terminating any borrowing or
loan, guarantee, security or indemnity arrangements in pursuance of the exercise
by the general partner of its rights and duties;
(j) all reasonable costs and expenses incurred in relation to obtaining consents or
convening and holding meetings of the limited partners;
(k) generally, all costs and expenses of, and/or incidental to, the preparation of
amendments to the Offering Documents;
(l) all reasonable costs and expenses of, and/or incidental to, the preparation and
dispatch to limited partners of all distributions, warrants, reports, circulars, forms
and notices and any other documents necessary or desirable in connection with the
business and administration of the Fund including the cost of any insurance
premiums paid by the Fund in connection thereto;
(m) all reasonable costs and expenses incurred as a result of termination of the Fund
and the realization of investment interests and other Fund assets pursuant thereto;
(n) any reasonable costs and expenses of any threatened or actual litigation involving
the Fund and the amount of any judgement or settlement paid in connection
therewith excluding however the costs and expenses of any litigation, judgement or
settlement as to which the general partner is not entitled to indemnity;
(o) any costs and expenses incurred in the preparation and filing of tax returns or
providing tax information to the partners;
(p) reasonable formation expenditures described in (and subject to the limitation set
forth in) the Offering Documents;
(q) indemnification payments and the cost of any insurance coverage acquired for the
protection of the Fund or any relevant party against any liability incurred in any
capacity which results in such person being a relevant party provided that such
person is serving in such capacity at the request of the Fund or the general partner;
... |
| Account Minimums and Types of Clients — Form ADV Part 2A (3/31/2026) [Brochure] |
|---|
TYPES OF CLIENTS As described in Item 4 of this Brochure, SV provides investment advisory services to pooled investment vehicles that operate as exempt investment companies pursuant to Sections 3(c)(1) and 3(c)(7) of the Investment Company Act. The Funds are limited to individuals and entities that meet the criteria of “qualified purchasers” as defined in Section 2(a)(51)(A) under the Investment Company Act. Prospective investors should refer to the Offering Documents of the applicable Fund for complete information on the minimum investment requirements for participation in such Fund. SV generally requires a minimum capital commitment for each of its Funds; however, the Firm maintains discretion to individually waive, increase or reduce the minimum investment required. In addition, SV offers co-investment opportunities to investors in the Fund(s) and/or to third parties. Participation in any transaction involving a Fund investment may only be extended to a person or entity if the Fund believes their involvement would benefit the consummation or success of the investment. In such situations, if co-investment opportunities are offered, the Firm will ensure that its Fund(s) receive proper allocation before extending further investment opportunities to existing limited partners and/or third parties. |
| Sector | Form 13F Holdings | Value ($M) | |
|---|---|---|---|
| Bicycle Therapeutics PLC | 21.1 | ||
| Bioventus Inc | 10.4 | ||
| Arsanis Inc | 0.5 | ||
| Holdings by Sector ($M) |
|---|
| Type | Form D Funds | Date | Sold | AUM |
|---|---|---|---|---|
| Other | SV7 Plus Growth Fund LP | [2025-03-31] | 35.6 M | |
| Offered $60,000,000 · Filed 2024-11-05 (D) · Exemption 506(b), 3(c), 3(c)(1), 3(c)(7) · Remaining $60,000,000 · Duration One year or less · Revenue Not Applicable | ||||
| VC | SV TREX CoInvestment LP | 2025-03-31 | 8.0 M | |
| Other | SV7 Growth Fund Strategic Partners LP | [2023-03-30] | 15.5 M | |
| Filed 2022-04-28 (D) · Exemption 506(b), 3(c), 3(c)(1), 3(c)(7) · Remaining Indefinite · Duration One year or less · Revenue Not Applicable | ||||
| VC | SV Life Sciences Fund IV CF LP | 2022-03-31 | 410.4 M | |
| VC | Medtech Convergence Fund LP | [2019-03-29] | 80.2 M | |
| Offered $94,000,000 · Filed 2019-03-12 (D) · Exemption 506(b), 3(c), 3(c)(7) · Remaining $94,000,000 · Duration One year or less · Revenue Not Applicable | ||||
| Other | SV7 Growth Fund LP | [2019-03-29] | 91.3 M | 155.3 M |
| Offered $250,000,000 · Filed 2020-11-10 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $500,000 · Remaining $158,690,177 · Duration More than one year · Revenue Not Applicable | ||||
| VC | DDF Parallel LLP | [2017-06-30] | 26.0 M | 19.3 M |
| Offered $302,381,000 · Filed 2017-10-17 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Remaining $276,413,669 · Duration More than one year · Revenue Not Applicable | ||||
| VC | SV Life Sciences Fund VI Strategic Partners LP | [2017-06-30] | 13.1 M | 8.7 M |
| Offered $13,130,000 · Filed 2017-04-12 (D) · Exemption 506(b), 3(c), 3(c)(1) · Duration One year or less · Revenue Not Applicable | ||||
| VC | SV Life Sciences Fund VI Strategic Partners LP | [2017-06-30] | 13.1 M | 13.3 M |
| Offered $13,130,000 · Filed 2017-04-12 (D) · Exemption 506(b), 3(c), 3(c)(1) · Duration One year or less · Revenue Not Applicable | ||||
| VC | Dementia Discovery LP | [2016-03-30] | 26.0 M | 169.6 M |
| Offered $302,381,000 · Filed 2017-10-17 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Remaining $276,413,669 · Duration More than one year · Revenue Not Applicable | ||||
| View All | ||||
| AUM Breakdown | Accounts | AUM ($B) |
|---|---|---|
| By Client Type | ||
| (a) Individuals (other than high net worth individuals) | 0 | 0.0 |
| (b) Individuals (high net worth individuals) | 0 | 0.0 |
| (c) Banking or thrift institutions | 0 | 0.0 |
| (d) Investment companies | 0 | 0.0 |
| (e) Business development companies | 0 | 0.0 |
| (f) Pooled investment vehicles | 21 | 1.1 |
| (g) Pension and profit sharing plans | 0 | 0.0 |
| (h) Charitable organizations | 0 | 0.0 |
| (i) State or municipal government entities | 0 | 0.0 |
| (j) Other investment advisers | 0 | 0.0 |
| (k) Insurance companies | 0 | 0.0 |
| (l) Sovereign wealth funds and foreign official institutions | 0 | 0.0 |
| (m) Corporations or other businesses not listed above | 0 | 0.0 |
| (n) Other | 0 | 0.0 |
| Total | 15 | 1.1 |
| By Discretionary | ||
| Discretionary | 15 | 1.1 |
| Non-Discretionary | 0 | 0.0 |
| Total | 15 | 1.1 |
| By Non-United States Persons | ||
| Non-United States Persons | 0.0 | |
| United States Persons | 1.1 | |
| Total | 15 | 1.1 |
| Form D Directors | Role | # Filings | # Firms | 2011 - 2026 |
|---|---|---|---|---|
| Michael Ross | Executive Officer | 88 | 5 | |
| James Garvey | Executive Officer | 42 | 4 | |
| Michael Balmuth | Executive Officer | 19 | 3 | |
| Kate Bingham | Executive Officer | 8 | 3 | |
| Paul Laviolette | Executive Officer | 59 | 2 | |
| David Milne | Executive Officer | 40 | 2 | |
| Thomas Flynn | Executive Officer | 34 | 2 | |
| Aaron Sandoski | Executive Officer | 21 | 2 | |
| Eugene Hill | Executive Officer | 20 | 2 | |
| Lutz Giebel | Executive Officer | 19 | 2 | |
| Greg Madden | Executive Officer | 12 | 2 | |
| Gregory Madden | Executive Officer | 5 | 2 | |
| Eugene Hill III | Executive Officer | 4 | 2 | |
| SV7 Growth Fund GP LLC | Executive Officer | 2 | 1 | |
| SVLSF V LLC | Director | 2 | 1 | |
| SVLSF VI LLC | Executive Officer | 2 | 1 | |
| SV Life Sciences Fund V GP LP | Director | 2 | 1 | |
| SV Life Sciences Fund VI GP LP | Executive Officer | 2 | 1 | |
| SV7 Plus Growth Fund GP LLC | Executive Officer | 1 | 1 | |
| Medtech Convergence GP LLC | Executive Officer | 1 | 1 |
| EDGAR Form | CIK | 2011 - 2026 |
|---|---|---|
| 13F-HR | [0001587143] |
| Firm Profile (Form ADV) | |
|---|---|
| Serves | Institutional |
| Comparable Firms | State | AUM |
|---|---|---|
|
NexPoint Real Estate Advisors X LP
✚
|
TX | 1,098.2 M |
|
Asset Consulting Group LLC
✚
|
MO | 1,096.1 M |
|
CS Capital Management Inc
✚
|
CA | 1,090.3 M |
|
Riot Ventures Management LLC
✚
|
CA | 1,086.1 M |
|
CIM Capital IC Management LLC
✚
|
CA | 1,080.5 M |
|
Power Sustainable Manager US Inc
✚
|
FL | 1,072.6 M |
|
Counterpointe Investment Management LLC
✚
|
CT | 1,067.7 M |
|
Twin Oak ETF Company
✚
|
MA | 1,057.8 M |
|
Nordea Investment Management North America Inc
✚
|
NY | 1,054.5 M |
|
Virtus Alternative Investment Advisers LLC
✚
|
CT | 1,053.0 M |